India, June 12 -- SAVA Healthcare Limited, a leading contract development and manufacturing organization (CDMO) in the Indian pharmaceutical sector, has received its first drug approval from the Drug Controller General of India (DCGI) for a combination nasal spray indicated for the treatment of allergic rhinitis with nasal congestion.

The approved formulation contains Fluticasone Furoate (27.5 mcg) and Oxymetazoline Hydrochloride (50 mcg) and is designed for targeted relief of allergy-induced nasal symptoms, including inflammation and congestion.

The product will be manufactured at SAVA Healthcare's state-of-the-art facility in Surendranagar, Gujarat, which complies with stringent regulatory requirements and quality standards.

Packaged...